RxDoctor Payments Data

Dinesha Weerasinghe, MD

Family Medicine · Pittsburgh, PANPI 1962604355

Payments from drug & device makers

$883in general payments, 2019–2025

Across 46 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$223
  • Amgen$130
  • Pfizer$127
  • GSK$92
  • Lilly USA, LLC$90
  • AbbVie$73
  • plus $149 from 8 others

What the payments were for

  • Food & beverage$883100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$883 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$29,370
Medicare patients
77
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$20,395
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,099
LinzessLinaclotide12$6,898
LokelmaSodium Zirconium Cyclosilicate11$4,344
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,249
Levothyroxine Sodium155$1,414
Rosuvastatin Calcium90$1,156
Lactulose39$1,001
Nano 2nd Gen Pen NeedlePen Needle, Diabetic15$796
Atorvastatin Calcium100$703
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate31$674
Levetiracetam14$547
Pantoprazole Sodium69$530
Omeprazole65$457
Losartan Potassium56$454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$30$20,39522 claims
GSKTrelegy Ellipta, Shingrix$92$17,34841 claims
AbbVieLinzess$73$6,89812 claims
AstraZenecaLokelma$11$4,34411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →